Medindia

X

China's Major Depression Drug Market will Triple by 2012

Tuesday, November 18, 2008 General News J E 4
Advertisement
WALTHAM, Mass, Nov. 17 Decision Resources, one of theworld's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, forecasts that the Chinese major depression drug marketwill triple by 2012, growing from $75 million in 2007 to $226 million in 2012.Selective serotonin reuptake inhibitors (SSRIs), the market-leading drugclass, will continue to experience strong double-digit growth, contributing tothe annual 20 percent growth of the major depression drug market during theforecast period.

According to the new Emerging Markets report entitled Major Depression inChina, this growth will be fueled in part by increasing urbanization and agreater exposure to risk factors.

"The risk of major depression among urban populations is more than fourtimes that of rural populations. Major depression is most common in urbanareas of China with over 75 percent of prevalent cases found in these areas in2007," stated Matthew Winton, Ph.D., analyst at Decision Resources.

The report also finds that Chinese physicians and patients prefer Westernmedicines to Chinese-manufactured products. Although Chinese physiciansgenerally regard Western-manufactured antidepressants as being of much higherquality than locally manufactured drugs, many Chinese-manufactured drugs haveachieved a majority of the market share, largely due to their lower prices.

"Western drug companies should consider competitive pricing of theirbranded drugs, relative to their Western competitors, as part of theirstrategic entry into China. Strategic pricing could offer multinationalcompanies a distinct competitive advantage in this rapidly growing market,"added Dr. Winton.

EMERGING MARKETS REPORTS

The Ultimate Analysis of Pharmaceutical Markets in China and India

Decision Resources is the FIRST and ONLY company to offer a syndicatedreport series for high-growth emerging markets with comprehensivedisease-specific analysis. Each report assesses the commercial opportunity inthe pharmaceutical market for a disease based on population demographics,economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in marketresearch publications, advisory services and consulting designed to helpclients shape strategy, allocate resources and master their chosen markets.Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offersbest-in-class, high-value information and insights on important sectors of thehealthcare industry. Clients rely on this analysis and data to make informeddecisions. Please visit Decision Resources, Inc. atwww.DecisionResourcesInc.com.

All company, brand or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 nmorales@dresources.com emarshall@dresources.com

SOURCE Decision Resources
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
SuperGen Appoints David Bearss, Ph.D., Chief Scien...
S
PRO Consulting Expands Scientific Expertise in Res...